174 related articles for article (PubMed ID: 19293806)
1. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.
Ueno H; Kaniwa N; Okusaka T; Ikeda M; Morizane C; Kondo S; Sugiyama E; Kim SR; Hasegawa R; Saito Y; Yoshida T; Saijo N; Sawada J
Br J Cancer; 2009 Mar; 100(6):870-3. PubMed ID: 19293806
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.
Sugiyama E; Kaniwa N; Kim SR; Kikura-Hanajiri R; Hasegawa R; Maekawa K; Saito Y; Ozawa S; Sawada J; Kamatani N; Furuse J; Ishii H; Yoshida T; Ueno H; Okusaka T; Saijo N
J Clin Oncol; 2007 Jan; 25(1):32-42. PubMed ID: 17194903
[TBL] [Abstract][Full Text] [Related]
4. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
[TBL] [Abstract][Full Text] [Related]
5. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Yonemori K; Ueno H; Okusaka T; Yamamoto N; Ikeda M; Saijo N; Yoshida T; Ishii H; Furuse J; Sugiyama E; Kim SR; Kikura-Hanajiri R; Hasegawa R; Saito Y; Ozawa S; Kaniwa N; Sawada J
Clin Cancer Res; 2005 Apr; 11(7):2620-4. PubMed ID: 15814642
[TBL] [Abstract][Full Text] [Related]
6. FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
Serdjebi C; Gagnière J; Desramé J; Fein F; Guimbaud R; François E; André T; Seitz JF; Montérymard C; Arsene D; Volet J; Abakar-Mahamat A; Lecomte T; Guerin-Meyer V; Legoux JL; Deplanque G; Guillet P; Ciccolini J; Lepage C; Dahan L
PLoS One; 2015; 10(8):e0135907. PubMed ID: 26308942
[TBL] [Abstract][Full Text] [Related]
7. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
Raynal C; Ciccolini J; Mercier C; Boyer JC; Polge A; Lallemant B; Mouzat K; Lumbroso S; Brouillet JP; Evrard A
Ther Drug Monit; 2010 Feb; 32(1):53-60. PubMed ID: 20010457
[TBL] [Abstract][Full Text] [Related]
8. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies.
Ciccolini J; Dahan L; André N; Evrard A; Duluc M; Blesius A; Yang C; Giacometti S; Brunet C; Raynal C; Ortiz A; Frances N; Iliadis A; Duffaud F; Seitz JF; Mercier C
J Clin Oncol; 2010 Jan; 28(1):160-5. PubMed ID: 19933910
[TBL] [Abstract][Full Text] [Related]
9. Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen.
Serdjebi C; Seitz JF; Ciccolini J; Duluc M; Norguet E; Fina F; Lacarelle B; Ouafik L; Dahan L
Pharmacogenomics; 2013 Jul; 14(9):1047-51. PubMed ID: 23837479
[TBL] [Abstract][Full Text] [Related]
10. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
Farrell JJ; Bae K; Wong J; Guha C; Dicker AP; Elsaleh H
Pharmacogenomics J; 2012 Oct; 12(5):395-403. PubMed ID: 21625252
[TBL] [Abstract][Full Text] [Related]
11. High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation.
Xu J; Zhou Y; Zhang J; Chen Y; Zhuang R; Liu T; Cai W
Clin Chim Acta; 2012 Aug; 413(15-16):1284-7. PubMed ID: 22546611
[TBL] [Abstract][Full Text] [Related]
12. Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
Ding X; Chen W; Fan H; Zhu B
Gene; 2015 Mar; 559(1):31-7. PubMed ID: 25582275
[TBL] [Abstract][Full Text] [Related]
13. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Maring JG; Wachters FM; Slijfer M; Maurer JM; Boezen HM; Uges DR; de Vries EG; Groen HJ
Eur J Clin Pharmacol; 2010 Jun; 66(6):611-7. PubMed ID: 20213492
[TBL] [Abstract][Full Text] [Related]
15. An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
Innocenti F; Jiang C; Sibley AB; Denning S; Etheridge AS; Watson D; Niedzwiecki D; Hatch AJ; Hurwitz HI; Nixon AB; Furukawa Y; Kubo M; Crona DJ; Kindler HL; McLeod HL; Ratain MJ; Owzar K
Pharmacogenet Genomics; 2019 Aug; 29(6):123-131. PubMed ID: 30889042
[TBL] [Abstract][Full Text] [Related]
16. Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report.
Connell CM; Brais R; Whitaker H; Upponi S; Beh I; Risdall J; Corrie P; Janowitz T; Jodrell DI
BMC Cancer; 2020 Jan; 20(1):38. PubMed ID: 31941506
[TBL] [Abstract][Full Text] [Related]
17. Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene.
Sugiyama E; Lee SJ; Lee SS; Kim WY; Kim SR; Tohkin M; Hasegawa R; Okuda H; Kawamoto M; Kamatani N; Sawada J; Kaniwa N; Saito Y; Shin JG
Drug Metab Pharmacokinet; 2009; 24(6):553-6. PubMed ID: 20045991
[TBL] [Abstract][Full Text] [Related]
18. Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis.
Kasuya K; Tsuchida A; Nagakawa Y; Suzuki Y; Suzuki M; Aoki T; Abe Y; Shimazu M; Itoi T; Sofuni A
Hepatogastroenterology; 2012; 59(117):1609-13. PubMed ID: 22155850
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach.
Serdjebi C; Gattacceca F; Seitz JF; Fein F; Gagnière J; François E; Abakar-Mahamat A; Deplanque G; Rachid M; Lacarelle B; Ciccolini J; Dahan L
Ther Drug Monit; 2017 Jun; 39(3):290-296. PubMed ID: 28346313
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs].
Saito Y
Yakugaku Zasshi; 2011 Feb; 131(2):239-46. PubMed ID: 21297369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
